Stuart B. Levy

Stuart B. Levy is a researcher and physician at Tufts University. He has advocated for greater awareness of antibiotic resistance.

Biography

Stuart B. Levy, M.D., Professor of Molecular Biology and Microbiology and of Medicine, is the Director of the Center for Adaptation Genetics and Drug Resistance at Tufts University School of Medicine and staff physician at the Tufts Medical Center.[1] He also serves as President of the International Alliance for the Prudent Use of Antibiotics, and is co-founder and Chief Scientific Officer of Paratek Pharmaceuticals, Inc.[1] He is a past President of the American Society for Microbiology.

Dr. Levy led the discovery of the first energy-dependent antibiotic efflux mechanism and efflux protein (for tetracyclines).[1] His research into multiple drug resistance revealed a regulatory locus, mar, for intrinsic antibiotic resistance and virulence among the Enterobacteriaceae and other bacteria.[1] He led the first, and perhaps only, prospective farm study showing that feed containing low dose antibiotics led to the emergence of antibiotic resistance in animals and the farm family.[1] He has published over 300 papers, edited four books and two special journal editions devoted to antibiotic use and resistance.[1] His 1992 book, The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle, now in its second edition, has been translated into four languages.[1]

Dr. Levy received his medical degree from the University of Pennsylvania, completed his residency at Mt. Sinai Hospital in New York and performed postdoctoral research at the National Institutes of Health.[1] He is a Fellow of the American College of Physicians, Infectious Disease Society of America, the American Academy of Microbiology and the American Association for the Advancement of Science.[1] He was Chairperson of the U.S. Fogarty Center study of “Antibiotic use and resistance worldwide” and helped write the U.S. Office of Technology Assessment report on antibiotic resistant bacteria.[1] He consults for international and national organizations including the World Health Organization, the U.S. National Academy of Sciences and Institute of Medicine, the U.S. FDA and U.S. EPA.[1] In 1995 he received the Hoechst Roussel Award for esteemed research in antimicrobial chemotherapy from the American Society for Microbiology and has been awarded honorary degrees from Wesleyan and Des Moines Universities.[1] Dr. Levy received the 2011 Hamao Umezawa Memorial Award by the International Society of Chemotherapy and the 2012 Abbott-ASM Lifetime Achievement Award.[2]

Views

Levy has summarized his message by saying that he wants "prudent use of antibiotics".[3]

The book Frontiers in antimicrobial resistance : a tribute to Stuart B. Levy is based on the work of Levy.[4]

Bibliography

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 National Science Advisory Board for Biosecurity; National Institutes of Health; Chinese Academy of Sciences (1 November 2013), "Stuart B. Levy, M.D." (PDF), Strengthening the Culture of Responsibility with Respect to Dual Use Research and Biosecurity, Bethesda, Maryland: National Institutes of Health, retrieved 27 October 2013
  2. ↑ https://paratekpharma.com/about/founders/
  3. ↑ Karen Weintraub; Stuart B. Levy (10 January 2011). "A leader of the resistance - The Boston Globe". The Boston Globe (Boston: NYTC). ISSN 0743-1791. Retrieved 27 October 2013.
  4. ↑ White, David G.; McDermott, Patrick F.; Alekshun, Michael N (2005). Frontiers in antimicrobial resistance : a tribute to Stuart B. Levy. Washington, DC: ASM Press. ISBN 978-1-55581-329-1.

External links

This article is issued from Wikipedia - version of the Friday, April 22, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.